MedTrace Logo

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

NCT07223411 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-11-26

No results posted yet for this study

Summary

This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.

Conditions

  • Locally Advanced Melanoma

Interventions

DRUG

Fianlimab + Cemiplimab

Patients treated with Fianlimab 1600 mg + Cemiplimab 350 mg under protocol NCT06246916

DRUG

Relatlimab + Nivolumab

Patients treated with Relatlimab 160 mg + Nivolumab 480 mg under protocol NCT06246916

Sponsors & Collaborators

Principal Investigators

  • John M Kirkwood, MD · UPMC Hillman Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-19
Primary Completion
2028-11-01
Completion
2031-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07223411 on ClinicalTrials.gov